Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now
Stake logo

BioNano Genomics Inc

1 day chart

Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.

Sign up and fund a new Wall St account and get a full U.S. share.

T&Cs apply
Claim now
Kickstart your portfolio with a U.S. stock on us

About BNGO

Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Buy US stocks in Australia starting with BNGO. Open an account and start investing today!

Market Capitalisation

$50.14M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

2.67M

High today

$0.81

Low today

$0.75

Open price

$0.80

52-week high

$6.76

52-week low

$0.71


What is Bionano Genomics and what do they do?

Put on your lab coat – this will get sciencey. Bionano Genomics is a global leader in the provision of optical genome mapping (OGM) solutions for genome analysis.

The company earns most of its revenue through sales of Saphyr, its genome mapping system, chip consumables, reagents and a suite of data analysis tools. 

According to Bionano Genomics, Saphyr allows researchers and clinicians “to accelerate the search for new diagnostics and therapeutic targets and to streamline the identification of structural changes in chromosomes, known as cytogenetics.”

Through their subsidiary, Lineagen, Bionano Genomics also runs diagnostic genetic testing for pediatric patients suspected of neurodevelopmental disabilities, in particular children.

The company was founded in 2003 by former Chief Scientific Officer and CEO, Han Cao. Bionano Genomics is currently headquartered in San Diego, California and run by CEO Erik Holmlin.

BNGO vs CRSP: What’s the difference between the two companies?

Bionano Genomics creates products and services that facilitate OGM and genome analysis.

CRISPR Therapeutics (CRSP) is focused on “transformative gene-based medicines for serious human diseases” using their very own gene-editing platform CRISPR-Cas9. Co-invented by the company’s founder, Dr. Emmanuelle Charpentier, CRISPR-Cas9 is used to treat blood disorders, cancers, diabetes and other diseases.

What type of stock is BNGO?

BNGO is a healthcare stock. The company sits in the instruments manufacturing industry and focuses on OGM and genome analysis.

Is BNGO profitable?

Bionano Genomics is currently unprofitable

In fact, the company’s operating income has gone deeper into the red over the past 3 years from minus US$26m in FY2019 to minus US$39m in FY2020 to minus US$77m in FY2021.

At the end of FY2021, Bionano Genomics’ free cash flow sat at minus US$73m.

Is BNGO a buy or sell?

Overall market sentiment on BNGO is mixed. 

Despite the decline in Bionano Genomics’ income, some investors are still bullish on the stock citing the Saphyr system as a true game changer in OGM and genome analysis.

Other investors see the consistent decline in operating income as a sign to sell. The BNGO share price has fallen 82% from over US$9.5 to a touch over US$1.5 over the past 12 months.

What is the short interest in BNGO?

As of 28th February 2022, Bionano Genomics’ short interest totaled 13.33% of all shares. This is up 0.55% from the previous month’s short interest.

Ready to start your investing journey with Stake?

Open an account

BNGO FAQs

Yes, the Stake platform allows you to buy BNGO shares and over 12,000 stocks and ETFs across the ASX and Wall St.

One share of BioNano Genomics Inc is valued at $0.77.

The ticker symbol for BioNano Genomics Inc is BNGO.

To buy BNGO stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in BNGO

The BioNano Genomics Inc 52-week high stock price is $6.76.

The BioNano Genomics Inc 52-week low stock price is $0.71.

As of 23/06/2024 BioNano Genomics Inc has a market cap of $50.14M.

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in BNGO
on Stake

Buy BNGO from US$3 brokerage

Invest in 9,500+ U.S. stocks and ETFs

Own a slice of BNGO from only US$10 with fractional shares

Get started
Canstar award phone
BNGO related stocks

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610105505, is an authorised representative (Authorised Representative No. 1241398) of Sanlam Private Wealth Pty Ltd (Australian Financial Services Licence No. 337927) ('Sanlam') and an authorised representative (Authorised Representative No. 1241398) of Airwallex Pty Ltd (Australian Financial Services Licence No. 487221) ('Airwallex'). Stake is not authorised by Airwallex under Airwallex’s AFSL to arrange for clients to be issued with securities as Airwallex is not authorised under its AFSL for this purpose. Stake is not authorised by Sanlam under Sanlam’s AFSL to arrange for clients to be issued with a non-cash payment facility as Sanlam is not authorised under its AFSL for this purpose. Stake SMSF Pty Ltd (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. Stakeshop Pty Ltd will also run marketing and promotions to you under. For more information about SMSFs, see our SMSF Risks page.The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers  before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2024 Stake. All rights reserved.